A Study Comparing the Effect of Nerve Flossing and Conventional Therapy with Only Conventional Therapy in Treating Sciatica
Corresponding Author(s) : M. Raja Srinivas
rajasrinivas18@gmail.com
International Journal of Allied Medical Sciences and Clinical Research,
Vol. 10 No. 4 (2022): 2022 Volume -10 - Issue 4
Abstract
Low back pain (SCIATICA) is a very common health problem world-wide and a major cause of disability affecting performance at work. Sciatica along with back pain accounts for more medical care and social cost which affects quality of life in most of the patients. To compare the effect of nerve flossing and conventional therapy with only conventional therapy in sciatica. A RCT was conducted on 30 subjects of age group 35 – 50 years, fulfilling the inclusion criteria. Pain intensity was measured by VAS and sciatica involvement assessed by SLR test. T test was used to comparison between them. The mean of VAS of pre-treatment for group A was 7.73 and for group B was 7.6 with P value 0.7203 which was considered as not significant. The mean of VAS of post treatment for group A was 7.26 and for group B was 2.26 with P value <0.0001 which was considered as extremely significant. The mean of ROM of pre-treatment for group A was 49.6 and for group B was 48 with P value 0.6709 which was considered as not significant. The mean of ROM of post treatment for group A was 50.8 and for group B was 61 with P value <0.0195 which was considered as extremely significant. Nerve flossing technique can be utilized with other modalities in the treatment of subacute sciatic patients due to low back ache for the relief of pain and sensory symptoms like tingling and numbness, restoration of spinal mobility and to minimize functional disability.
Keywords
VAS, ROM, Nerve flossing, Sciatica
1.
M. Raja Srinivas, G. Kalyan, J. Hari Kishore Babu, J. Bhaskar Rao, T. Sunil Kumar. A Study Comparing the Effect of Nerve Flossing and Conventional Therapy with Only Conventional Therapy in Treating Sciatica. Int. J. of Allied Med. Sci. and Clin. Res. [Internet]. 2022 Dec. 6 [cited 2026 Mar. 4];10(4):455-62. Available from: https://ijamscr.com/ijamscr/article/view/1268
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
References
-
1. Howard A, O'Donoghue M, Feeney A, Sleator RD. Acinetobacter baumannii: an emerging opportunistic pathogen. Virulence. 2012 May 1;3(3):243-50. doi: 10.4161/viru.19700.
2. Lahiri KK, Mani NS, Purai SS. Acinetobacter spp as Nosocomial Pathogen: Clinical Significance and Antimicrobial Sensitivity. Med J Armed Forces India. 2004 Jan;60(1):7-10. doi: 10.1016/S0377-1237(04)80148-5. Epub 2011 Jul 21. PMID: 27407568; PMCID: PMC4923491.
3. Sikora A, Zahra F. Nosocomial Infections. [Updated 2022 Sep 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559312/.
4. Khanna A, Khanna M, Aggarwal A. Serratia marcescens- a rare opportunistic nosocomial pathogen and measures to limit its spread in hospitalized patients. J ClinDiagn Res. 2013 Feb;7(2):243-6. doi: 10.7860/JCDR/2013/5010.2737.
5. Manchanda V, Sanchaita S, Singh N. Multidrug resistant Acinetobacter. J Glob Infect Dis. 2010 Sep;2(3):291-304. doi: 10.4103/0974-777X.68538.
6. George M. Eliopoulos, Lisa L. Maragakis, Trish M. Perl, Acinetobacter baumannii: Epidemiology, Antimicrobial Resistance, and Treatment Options, Clinical Infectious Diseases, Volume 46, Issue 8, 15 April 2008, Pages 1254–1263, https://doi.org/10.1086/529198.
7. Young LS, Sabel AL, Price CS et al. Epidemiologic, clinical and economic evaluation of an outbreak of multidrug resistant Acinetobacter baumannii infections in a surgical intensive unit. Infect Control Hosp Epidemiol. 2007; 28(11): 1247-54.
8. VanLooveren M, Goossens H. ARPAC steering Group. Antimicrobial resistance of Acinetobacter species in Europe. Clin Microbial Infect. 2004; 10(8): 684-704.
9. Callie Camp, Owatha L. Tatum, A Review of Acinetobacter baumannii as a Highly Successful Pathogen in Times of War, Laboratory Medicine, Volume 41, Issue 11, November 2010, Pages 649–657, https://doi.org/10.1309/LM90IJNDDDWRI3RE.
10. Al Bshabshe, A., Joseph, M. R., Al Hussein, A., Haimour, W., & Hamid, M. E. (2016). Multidrug resistance Acinetobacter species at the intensive care unit, Aseer Central Hospital, Saudi Arabia: A one year analysis. Asian Pacific journal of tropical medicine, 9(9), 903-908.
11. Raina D, Sharma N, Mahawal B et al. Speciation and antibiotic resistance pattern of Acinetobacter spp in a tertiary care hospital in Uttarakhand. IntJourn of Med Research & Health Sci. 2016; 5(4): 89-96.
12. Malathy, K. (2015). Identification, Speciation, Antibiogram and Molecular Characterization of Acinetobacter Isolated from Various Clinical Samples received in Microbiology Laboratory, Thanjavur Medical College and Hospital (Doctoral dissertation, Thanjavur Medical College, Thanjavur).
13. Rajkumari, S., Pradhan, S., Sharma, D., & Jha, B. (2020). Prevalence and Antibiogram of Acinetobacter Species Isolated from Various Clinical Samples in a Tertiary Care Hospital. Journal of College of Medical Sciences-Nepal, 16(1), 26-32.
14. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 22nd informational supplement, CLSI document M100-S22. Wayne PA: Clinical and Laboratory Standards Institute; 2014.
15. Sarshar, M., Behzadi, P., Scribano, D., Palamara, A. T., &Ambrosi, C. (2021). Acinetobacter baumannii: an ancient commensal with weapons of a pathogen. Pathogens, 10(4), 387.
16. Rangel, K., Chagas, T. P. G., & De-Simone, S. G. (2021). Acinetobacter baumannii infections in times of COVID-19 pandemic. Pathogens, 10(8), 1006.
17. Alotaibi, T., Abuhaimed, A., Alshahrani, M., Albdelhady, A., Almubarak, Y., & Almasari, O. (2021). Prevalence of multidrug-resistant Acinetobacter baumannii in a critical care setting: A tertiary teaching hospital experience. SAGE Open Medicine, 9, 20503121211001144.
18. Ababneh, Q., Abulaila, S., &Jaradat, Z. (2022). Isolation of extensively drug resistant Acinetobacter baumannii from environmental surfaces inside intensive care units. American Journal of Infection Control, 50(2), 159-165.
19. Gupta, N., Gandham, N., Jadhav, S., & Mishra, R. N. (2015). Isolation and identification of Acinetobacter species with special reference to antibiotic resistance. Journal of natural science, biology, and medicine, 6(1), 159.
20. Mohammed, S. H., Ahmed, M. M., AbdAlameer Abd Alredaa, N., HaiderAbdAlabbas, H., Mohammad Ali, Z. D., Abed Al-Wahab, Z. Z., ... & Yahya Abid Zaid, N. (2022). Prevalence of Acinetobacter Species Isolated from Clinical Samples Referred to Al-Kafeel Hospital, Iraq and Their Antibiotic Susceptibility Patterns from 2017-2021. Iranian Journal of Medical Microbiology, 16(1), 76-82.
21. Albayrak, H., Bayraktar, M. T., &Zeyrek, F. Y. (2021). Antibiotic Resistance Profile of Acinetobacter Species Isolated from Blood Cultures of Inpatients in Harran University Hospital. Harran ÜniversitesiT?pFakültesiDergisi, 18(2), 165-169.
22. Dash, M., Padhi, S., Pattnaik, S., Mohanty, I., &Misra, P. (2013). Frequency, risk factors, and antibiogram of Acinetobacter species isolated from various clinical samples in a tertiary care hospital in Odisha, India. Avicenna Journal of Medicine, 3(04), 97-102.
23. https://1library.net/document/7q01nmvz-multivariate-analysis-acinetobacter-species-tertiary-care-hospital.html.
24. Gajdács, M., Burián, K., &Terhes, G. (2019). Resistance levels and epidemiology of non-fermenting gram-negative bacteria in urinary tract infections of inpatients and outpatients (RENFUTI): a 10-year epidemiological snapshot. Antibiotics, 8(3), 143.
References
1. Howard A, O'Donoghue M, Feeney A, Sleator RD. Acinetobacter baumannii: an emerging opportunistic pathogen. Virulence. 2012 May 1;3(3):243-50. doi: 10.4161/viru.19700.
2. Lahiri KK, Mani NS, Purai SS. Acinetobacter spp as Nosocomial Pathogen: Clinical Significance and Antimicrobial Sensitivity. Med J Armed Forces India. 2004 Jan;60(1):7-10. doi: 10.1016/S0377-1237(04)80148-5. Epub 2011 Jul 21. PMID: 27407568; PMCID: PMC4923491.
3. Sikora A, Zahra F. Nosocomial Infections. [Updated 2022 Sep 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559312/.
4. Khanna A, Khanna M, Aggarwal A. Serratia marcescens- a rare opportunistic nosocomial pathogen and measures to limit its spread in hospitalized patients. J ClinDiagn Res. 2013 Feb;7(2):243-6. doi: 10.7860/JCDR/2013/5010.2737.
5. Manchanda V, Sanchaita S, Singh N. Multidrug resistant Acinetobacter. J Glob Infect Dis. 2010 Sep;2(3):291-304. doi: 10.4103/0974-777X.68538.
6. George M. Eliopoulos, Lisa L. Maragakis, Trish M. Perl, Acinetobacter baumannii: Epidemiology, Antimicrobial Resistance, and Treatment Options, Clinical Infectious Diseases, Volume 46, Issue 8, 15 April 2008, Pages 1254–1263, https://doi.org/10.1086/529198.
7. Young LS, Sabel AL, Price CS et al. Epidemiologic, clinical and economic evaluation of an outbreak of multidrug resistant Acinetobacter baumannii infections in a surgical intensive unit. Infect Control Hosp Epidemiol. 2007; 28(11): 1247-54.
8. VanLooveren M, Goossens H. ARPAC steering Group. Antimicrobial resistance of Acinetobacter species in Europe. Clin Microbial Infect. 2004; 10(8): 684-704.
9. Callie Camp, Owatha L. Tatum, A Review of Acinetobacter baumannii as a Highly Successful Pathogen in Times of War, Laboratory Medicine, Volume 41, Issue 11, November 2010, Pages 649–657, https://doi.org/10.1309/LM90IJNDDDWRI3RE.
10. Al Bshabshe, A., Joseph, M. R., Al Hussein, A., Haimour, W., & Hamid, M. E. (2016). Multidrug resistance Acinetobacter species at the intensive care unit, Aseer Central Hospital, Saudi Arabia: A one year analysis. Asian Pacific journal of tropical medicine, 9(9), 903-908.
11. Raina D, Sharma N, Mahawal B et al. Speciation and antibiotic resistance pattern of Acinetobacter spp in a tertiary care hospital in Uttarakhand. IntJourn of Med Research & Health Sci. 2016; 5(4): 89-96.
12. Malathy, K. (2015). Identification, Speciation, Antibiogram and Molecular Characterization of Acinetobacter Isolated from Various Clinical Samples received in Microbiology Laboratory, Thanjavur Medical College and Hospital (Doctoral dissertation, Thanjavur Medical College, Thanjavur).
13. Rajkumari, S., Pradhan, S., Sharma, D., & Jha, B. (2020). Prevalence and Antibiogram of Acinetobacter Species Isolated from Various Clinical Samples in a Tertiary Care Hospital. Journal of College of Medical Sciences-Nepal, 16(1), 26-32.
14. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 22nd informational supplement, CLSI document M100-S22. Wayne PA: Clinical and Laboratory Standards Institute; 2014.
15. Sarshar, M., Behzadi, P., Scribano, D., Palamara, A. T., &Ambrosi, C. (2021). Acinetobacter baumannii: an ancient commensal with weapons of a pathogen. Pathogens, 10(4), 387.
16. Rangel, K., Chagas, T. P. G., & De-Simone, S. G. (2021). Acinetobacter baumannii infections in times of COVID-19 pandemic. Pathogens, 10(8), 1006.
17. Alotaibi, T., Abuhaimed, A., Alshahrani, M., Albdelhady, A., Almubarak, Y., & Almasari, O. (2021). Prevalence of multidrug-resistant Acinetobacter baumannii in a critical care setting: A tertiary teaching hospital experience. SAGE Open Medicine, 9, 20503121211001144.
18. Ababneh, Q., Abulaila, S., &Jaradat, Z. (2022). Isolation of extensively drug resistant Acinetobacter baumannii from environmental surfaces inside intensive care units. American Journal of Infection Control, 50(2), 159-165.
19. Gupta, N., Gandham, N., Jadhav, S., & Mishra, R. N. (2015). Isolation and identification of Acinetobacter species with special reference to antibiotic resistance. Journal of natural science, biology, and medicine, 6(1), 159.
20. Mohammed, S. H., Ahmed, M. M., AbdAlameer Abd Alredaa, N., HaiderAbdAlabbas, H., Mohammad Ali, Z. D., Abed Al-Wahab, Z. Z., ... & Yahya Abid Zaid, N. (2022). Prevalence of Acinetobacter Species Isolated from Clinical Samples Referred to Al-Kafeel Hospital, Iraq and Their Antibiotic Susceptibility Patterns from 2017-2021. Iranian Journal of Medical Microbiology, 16(1), 76-82.
21. Albayrak, H., Bayraktar, M. T., &Zeyrek, F. Y. (2021). Antibiotic Resistance Profile of Acinetobacter Species Isolated from Blood Cultures of Inpatients in Harran University Hospital. Harran ÜniversitesiT?pFakültesiDergisi, 18(2), 165-169.
22. Dash, M., Padhi, S., Pattnaik, S., Mohanty, I., &Misra, P. (2013). Frequency, risk factors, and antibiogram of Acinetobacter species isolated from various clinical samples in a tertiary care hospital in Odisha, India. Avicenna Journal of Medicine, 3(04), 97-102.
23. https://1library.net/document/7q01nmvz-multivariate-analysis-acinetobacter-species-tertiary-care-hospital.html.
24. Gajdács, M., Burián, K., &Terhes, G. (2019). Resistance levels and epidemiology of non-fermenting gram-negative bacteria in urinary tract infections of inpatients and outpatients (RENFUTI): a 10-year epidemiological snapshot. Antibiotics, 8(3), 143.
2. Lahiri KK, Mani NS, Purai SS. Acinetobacter spp as Nosocomial Pathogen: Clinical Significance and Antimicrobial Sensitivity. Med J Armed Forces India. 2004 Jan;60(1):7-10. doi: 10.1016/S0377-1237(04)80148-5. Epub 2011 Jul 21. PMID: 27407568; PMCID: PMC4923491.
3. Sikora A, Zahra F. Nosocomial Infections. [Updated 2022 Sep 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559312/.
4. Khanna A, Khanna M, Aggarwal A. Serratia marcescens- a rare opportunistic nosocomial pathogen and measures to limit its spread in hospitalized patients. J ClinDiagn Res. 2013 Feb;7(2):243-6. doi: 10.7860/JCDR/2013/5010.2737.
5. Manchanda V, Sanchaita S, Singh N. Multidrug resistant Acinetobacter. J Glob Infect Dis. 2010 Sep;2(3):291-304. doi: 10.4103/0974-777X.68538.
6. George M. Eliopoulos, Lisa L. Maragakis, Trish M. Perl, Acinetobacter baumannii: Epidemiology, Antimicrobial Resistance, and Treatment Options, Clinical Infectious Diseases, Volume 46, Issue 8, 15 April 2008, Pages 1254–1263, https://doi.org/10.1086/529198.
7. Young LS, Sabel AL, Price CS et al. Epidemiologic, clinical and economic evaluation of an outbreak of multidrug resistant Acinetobacter baumannii infections in a surgical intensive unit. Infect Control Hosp Epidemiol. 2007; 28(11): 1247-54.
8. VanLooveren M, Goossens H. ARPAC steering Group. Antimicrobial resistance of Acinetobacter species in Europe. Clin Microbial Infect. 2004; 10(8): 684-704.
9. Callie Camp, Owatha L. Tatum, A Review of Acinetobacter baumannii as a Highly Successful Pathogen in Times of War, Laboratory Medicine, Volume 41, Issue 11, November 2010, Pages 649–657, https://doi.org/10.1309/LM90IJNDDDWRI3RE.
10. Al Bshabshe, A., Joseph, M. R., Al Hussein, A., Haimour, W., & Hamid, M. E. (2016). Multidrug resistance Acinetobacter species at the intensive care unit, Aseer Central Hospital, Saudi Arabia: A one year analysis. Asian Pacific journal of tropical medicine, 9(9), 903-908.
11. Raina D, Sharma N, Mahawal B et al. Speciation and antibiotic resistance pattern of Acinetobacter spp in a tertiary care hospital in Uttarakhand. IntJourn of Med Research & Health Sci. 2016; 5(4): 89-96.
12. Malathy, K. (2015). Identification, Speciation, Antibiogram and Molecular Characterization of Acinetobacter Isolated from Various Clinical Samples received in Microbiology Laboratory, Thanjavur Medical College and Hospital (Doctoral dissertation, Thanjavur Medical College, Thanjavur).
13. Rajkumari, S., Pradhan, S., Sharma, D., & Jha, B. (2020). Prevalence and Antibiogram of Acinetobacter Species Isolated from Various Clinical Samples in a Tertiary Care Hospital. Journal of College of Medical Sciences-Nepal, 16(1), 26-32.
14. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 22nd informational supplement, CLSI document M100-S22. Wayne PA: Clinical and Laboratory Standards Institute; 2014.
15. Sarshar, M., Behzadi, P., Scribano, D., Palamara, A. T., &Ambrosi, C. (2021). Acinetobacter baumannii: an ancient commensal with weapons of a pathogen. Pathogens, 10(4), 387.
16. Rangel, K., Chagas, T. P. G., & De-Simone, S. G. (2021). Acinetobacter baumannii infections in times of COVID-19 pandemic. Pathogens, 10(8), 1006.
17. Alotaibi, T., Abuhaimed, A., Alshahrani, M., Albdelhady, A., Almubarak, Y., & Almasari, O. (2021). Prevalence of multidrug-resistant Acinetobacter baumannii in a critical care setting: A tertiary teaching hospital experience. SAGE Open Medicine, 9, 20503121211001144.
18. Ababneh, Q., Abulaila, S., &Jaradat, Z. (2022). Isolation of extensively drug resistant Acinetobacter baumannii from environmental surfaces inside intensive care units. American Journal of Infection Control, 50(2), 159-165.
19. Gupta, N., Gandham, N., Jadhav, S., & Mishra, R. N. (2015). Isolation and identification of Acinetobacter species with special reference to antibiotic resistance. Journal of natural science, biology, and medicine, 6(1), 159.
20. Mohammed, S. H., Ahmed, M. M., AbdAlameer Abd Alredaa, N., HaiderAbdAlabbas, H., Mohammad Ali, Z. D., Abed Al-Wahab, Z. Z., ... & Yahya Abid Zaid, N. (2022). Prevalence of Acinetobacter Species Isolated from Clinical Samples Referred to Al-Kafeel Hospital, Iraq and Their Antibiotic Susceptibility Patterns from 2017-2021. Iranian Journal of Medical Microbiology, 16(1), 76-82.
21. Albayrak, H., Bayraktar, M. T., &Zeyrek, F. Y. (2021). Antibiotic Resistance Profile of Acinetobacter Species Isolated from Blood Cultures of Inpatients in Harran University Hospital. Harran ÜniversitesiT?pFakültesiDergisi, 18(2), 165-169.
22. Dash, M., Padhi, S., Pattnaik, S., Mohanty, I., &Misra, P. (2013). Frequency, risk factors, and antibiogram of Acinetobacter species isolated from various clinical samples in a tertiary care hospital in Odisha, India. Avicenna Journal of Medicine, 3(04), 97-102.
23. https://1library.net/document/7q01nmvz-multivariate-analysis-acinetobacter-species-tertiary-care-hospital.html.
24. Gajdács, M., Burián, K., &Terhes, G. (2019). Resistance levels and epidemiology of non-fermenting gram-negative bacteria in urinary tract infections of inpatients and outpatients (RENFUTI): a 10-year epidemiological snapshot. Antibiotics, 8(3), 143.